

Haematologica
HAEMATOL/2019/223743
Version 3

A cross-trial comparison of single-agent ibrutinib versus
chlorambucil-obinutuzumab in previously untreated patients with
chronic lymphocytic leukemia or small lymphocytic lymphoma

Alessandra Tedeschi, Richard Greil, Fatih Demirkan, Tadeusz Robak,
Carol Moreno, Paul M. Barr, Bertrand Anz, David Simpson, Gianluca
Gaidano, Osnat Bairey, Don Stevens, Devinder Gill, Ian W. Flinn,
Thomas J. Kipps, Jan A. Burger, Jennifer Lin, Thomas Webb, Viktor
Fedorov, Lori Styles, and John G. Gribben

Disclosures: A. Tedeschi: Consulting or advisory role – Janssen spa, Gilead, AbbVie, Sunesis; Speakers bureau – Janssen; R. Greil: Honoraria – Celgene, Roche, Takeda, AstraZeneca, Novartis, Amgen, Bristol-Myers Squibb, Merck, Sandoz; Consulting or advisory role – Celgene, Novartis, Roche, Bristol-Myers Squibb, Takeda, AbbVie, AstraZeneca, Janssen; Research funding – Celgene, Roche, Takeda, AstraZeneca, Novartis, Amgen, Bristol-Myers Squibb, Merck, Sandoz; Travel/accommodations expenses – Roche, Amgen, Janssen, AstraZeneca; F. Demirkan: Consulting or advisory role – Amgen, AbbVie; Research funding – Janssen, AbbVie; Travel/accommodations expenses – AbbVie, Pfizer, Janssen, Amgen; T. Robak: Research funding – Pharmacyclics LLC, an AbbVie Company; C. Moreno: Consulting or advisory role – Pharmacyclics LLC, an AbbVie Company, Janssen, AbbVie; P. Barr: Consulting or advisory role – Pharmacyclics LLC, an AbbVie Company, AbbVie; Research funding – Pharmacyclics LLC, an AbbVie Company; B. Anz: nothing to disclose; D. Simpson: Honoraria – Celgene, Roche, Merck, Janssen; Research funding – Amgen, Merck, Pharmacyclics LLC, an AbbVie Company, AbbVie, Sanofi, Roche, BeiGene, Acerta; Travel/accommodations expenses – Celgene, Bristol-Myers Squibb, Novartis; G. Gaidano: Honoraria – Roche, Janssen, Gilead, AbbVie, MorphoSys; Consulting or advisory role – Roche, Janssen, Gilead, AbbVie, MorphoSys; Research funding – Amgen; Speakers bureau – Janssen, AbbVie, Gilead; Travel/accommodations expenses – Janssen, Gilead, AbbVie, Roche; O. Bairey: Consulting or advisory role – AbbVie; Research funding – Janssen (investigator initiation grant); D. Stevens: Consulting or advisory role – Bayer; D. Gill: Honoraria – Janssen Cilag; Consulting or advisory role – Janssen Cilag; I. Flinn: Research funding – Agios, ArQule, BeiGene, Calithera, Celgene, Constellation, Curis, Forma, Forty Seven, Genentech, Gilead, Incyte, Infinity, Janssen, KITE, Merck, Novartis, Pfizer, Pharmacyclics LLC, an AbbVie Company, Portola, Seattle Genetics, Takeda, TG Therapeutics, Trillium, Verastem; T. Kipps: Consulting or advisory role – AbbVie, Genentech-Roche, Gilead, Pharmacyclics LLC, an AbbVie Company, Celgene; Research funding – AbbVie, Genentech-Roche, Pharmacyclics LLC, an AbbVie Company, Oncternal; J. Burger: Honoraria – Janssen; Consulting or advisory role – Janssen; Research funding – Gilead, TG Therapeutics, Pharmacyclics LLC, an AbbVie Company, BeiGene; Travel/accommodations expenses – Gilead, TG Therapeutics, Pharmacyclics LLC, an AbbVie Company, Novartis, Janssen; J. Lin: Employment – Pharmacyclics LLC, an AbbVie Company; Stock – AbbVie; T. Webb: Employment – Janssen; Stock – Johnson & Johnson; V. Fedorov: Employment – Pharmacyclics GmbH, an AbbVie Company; Stock – AbbVie; L. Styles: Employment – Pharmacyclics LLC, an AbbVie Company; Stock – AbbVie; J. Gribben: Honoraria – Pharmacyclics LLC, an AbbVie Company, Janssen; Consulting or advisory role – Pharmacyclics LLC, an AbbVie Company, Janssen; Research funding – Janssen

Contributions: AT, JL, VF, and LS designed the analysis; AT, RG, FD, TR, CM, PB, BA, DS, GG, OB, DS, DG, IWF, TJK, JAB, and JGG collected data; JL, VF, and LS confirmed the accuracy of the data and compiled it for analysis; JL performed statistical analysis; all authors had access to the data and were involved in the interpretation of data. All authors contributed to the manuscript preparation and approved the final version of the manuscript for submission.